Testing effectiveness (Phase 2)Not Yet RecruitingNCT07231575
What this trial is testing
Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC
Who this might be right for
Neoadjuvant ImmunotherapyNSCLCChemo-free Therapy
Sun Yat-sen University 39